Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.
Sibeprenlimab is under clinical development by Visterra and currently in Phase III for IgA Nephropathy (Berger’s Disease). According to GlobalData, Phase III drugs for IgA Nephropathy (Berger’s ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...